Program
pocenbrodib
Also written as “Pocenbrodib”, “Pocenbrodib and Darolutamide” and “FT-7051”.
Its studies are mostly in Prostatic Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 10 open or running | phase 1since Sep 24, 2020 | Sep 24, 2020 | none ahead |
| Pathos AI | 11 open or running | phase 2since Dec 10, 2024 | Dec 10, 2024 | Jun 30, 2028phase 2 · NCT06785636 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 24, 2020First study: phase 1 study in Prostatic NeoplasmsNew to Novo NordiskNovo Nordisk · NCT04575766 · 25 enrolled · United States
- Dec 10, 2024Pathos AI's first study: phase 2 study in Prostatic NeoplasmsNew to Pathos AIPathos AI · NCT06785636 · 120 planned · United States
Ahead
- Jun 30, 2028Primary completion: phase 2 study in Prostatic NeoplasmsPathos AI · NCT06785636
TargetBeta
“An orally bioavailable inhibitor of the bromodomain of the histone acetyltransferase (HAT) paralogs, CREB binding protein (CBP) and p300 (E1A-associated protein p300; p300 HAT), ”NCIt, by rule
Other programs on OPN1LW
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| inobrodibrule | cellcentric-ltd | phase 3 | 4 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06785636Prostatic Neoplasms · United States | 2 | Recruiting | Pathos AI | Jun 30, 2028 | 120 |
| NCT04575766Prostatic Neoplasms · United States | 1 | Terminated | Novo Nordisk | Nov 8, 2022 | 25 |
How it is read
Names in the registry
- “Pocenbrodib”, 1 entry
- “Pocenbrodib and Darolutamide”, 1 entry
- “FT-7051”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.